Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform

Collaboration Agreement:
Sanofi and Alloy Therapeutics have entered into a target-specific collaboration and license agreement to develop a central nervous system (CNS) drug using Alloy's AntiClastic Antisense Platform123.

Financial Terms:
Alloy will receive up to $27.5 million in upfront and preclinical milestone payments, and is eligible for over $400 million in discovery, development, and commercial milestone payments, along with tiered royalties on sales of any resulting products123.

Technology Overview:
Alloy's AntiClastic Antisense Platform is designed to overcome potency and therapeutic index challenges in antisense drugs by reaching intracellular disease targets at the RNA level, leveraging a novel spatial conformation of oligonucleotides developed by Sudhir Agrawal123.

Development Goals:
The collaboration aims to develop a novel class of genetic medicine capable of crossing the blood-brain barrier, leveraging Sanofi's neuroscience expertise and Alloy's antisense technology123.

Strategic Partnership:
This partnership underscores Alloy's commitment to open collaboration and accessible technologies, and Sanofi's focus on developing targeted, potentially disease-modifying therapies for neurological conditions123.

Sources:

1. https://alloytx.com/2025/01/07/alloy-therapeutics-announces-target-specific-collaboration-with-sanofi/

2. https://www.worldpharmaceuticals.net/news/sanofi-alloy-therapeutics-partner-for-anticlastic-antisense-platform/

3. https://pmlive.com/pharma_news/sanofi-and-alloy-therapeutics-enter-central-nervous-system-deal-worth-over-427m/